What's the Difference Between a Patent Grant and a Patent Application?

Here's the reader question that trips up almost everyone scanning biotech news: a company "has a patent" on something — but does it? Often the headline is describing a patent application, not a granted patent, and the difference is the difference between owning a right and asking for one.

Start with the granted patent. When a patent office examines an application and decides the claims are new and valid, it issues the patent. From that point the owner has an enforceable right: they can sue a competitor for infringement. You can spot grants in the record by their issue date and kind code — a US grant typically carries a "B2" suffix. For example, Eli Lilly's US12616740B2 is a granted patent, issued May 5, 2026. That "B2" and the issue date tell you it's enforceable.

Now the published application. While an application is still under review, it's usually published for the public to see — but publication is not approval. It carries a code like "A1" and a publication date, not an issue date, and crucially it confers no enforceable rights yet. The tri-agonist filing US20260151493A1 is a published application: a request describing claims the office has not yet allowed. The company is staking a position, not holding a weapon.

Why does this decide real money in biotech? Because a granted patent can block a competitor's product launch, while a pending application generally cannot. Treating an A1 publication as if it were a B2 grant can lead a reader to overestimate how protected a drug is — or how blocked a rival is. The codes are small, but they carry the entire legal weight.

There's a second, subtler reason to read the type carefully. Applications reveal intent and direction — they show what a company is trying to claim, which is genuinely useful for understanding strategy. But the claims in a published application frequently get narrowed before they're granted, or rejected entirely. So an application tells you where someone is aiming; only a grant tells you what they actually hit.

The rule of thumb, then, lead with the type. Before you conclude anything from "Company X patented Y," check whether the record is a grant (issued, B2, enforceable) or an application (published, A1, pending). On this site, every patent we cite is labeled and deep-linked so you can verify it yourself — because in biotech, the gap between a grant and an application is the gap between protection and hope.